Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma ...(July 2000 and March2002. Patients betwee...),Health

Date:10/30/2007

July 2000 and March 2002. Patients between the ages of 18-70 years with newly diagnosed GBM were eligible. Patients received either focal radiotherapy plus temozolomide at 75mg/meters squared daily continuously for 42 (up to 49) days, followed by up to six cycles of adjuvant temozolomide (150-200 mg/meters squared daily for five days every 28 days) or focal radiotherapy alone. Primary endpoint of the study was overall survival, with secondary endpoints of progression-free survival and quality of life. Initial study results presented in 2004 at the annual meeting of the American Society of Clinical Oncology and fully published in the New England Journal of Medicine in March 2005, found a median overall survival of 14.6 months in patients treated with TEMODAR concomitantly with radiotherapy and then as maintenance treatment compared to a median survival of 12.1 months in those treated with radiotherapy alone. The hazard ration (HR) for overall survival was 0.63 (95 percent CI for HR equal to 0.52-0.75) with a log-rank p less than 0.0001 in favor of the TEMODAR arm.

About Glioblastoma multiforme

Glioblastoma multiforme is a rapidly growing tumor of the central nervous system, most often located in the brain. It is the most common and deadliest type of primary brain tumor. GBM is more common among males, particularly men between the ages of 40 and 60 years, and occurs more frequently in Caucasians. The overall annual incidence of primary malignant brain tumors is six to seven per 100,000 people. (1)

Important Information Regarding U.S. Labeling for TEMODAR

TEMODAR(R) (temozolomide) Capsules are indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.

In newly diagnosed glioblastoma multiforme, during the concomitant phase (TEMODAR plus radiotherapy) side effects including thrombocytopenia, nausea, vomiting, anorexia and constipation, were m
'/>"/>

SOURCE Schering-Plough Corp. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
3. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
4. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
5. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
6. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
7. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
8. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. UCB Presents Long-Term CImzia Data in Crohns Disease
11. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week